Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-806 in moderate to severe plaque psoriasis
NCT05896527Phase 2Completed
- Sponsor
- DICE Therapeutics
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of navepdekinra in plaque psoriasis, sponsored by DICE Therapeutics. Started May 2023; status: completed.
02
Drugs
navepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05896527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896527.